3625 results about "Antigen Binding Fragment" patented technology

The invention discloses preparation of a targeting LYPD3 antibody and application of the targeting LYPD3 antibody in tumor immunotherapy. The antibody or antigen binding fragment thereof comprises a heavy chain variable region having CDR-H1, CDR-H2 and CDR-H3 and a light chain variable region having CDR-L1, CDR-L2 and CDR-L3 wherein CDR-H1, CDR-H2 and CDR-H3 comprise the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, and CDR-L1, CDR-L2 and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

The invention provides a monoclonal antibody of a p-Tau217 protein and an application of the monoclonal antibody. In particular, the present invention provides an antibody or an antigen binding fragment thereof targeting a p-Tau217 protein. The antibody provided by the invention can specifically recognize and bind the p-Tau217 protein, does not recognize p-Tau181 and non-phosphorylated Tau protein, and can be used for preparing a detection preparation or a kit for diagnosing diseases related to the p-Tau217 protein, such as Alzheimer's disease.

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to TNF-like ligand 1A (TL1A). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing same, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention, as well as to pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds; to methods for treating TL1A-mediated diseases or disorders, to use of the antibody or antigen-binding fragment thereof or pharmaceutical composition thereof for treating TL1A-mediated diseases or disorders, and to use of the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds for treating TL1A-mediated diseases or disorders.

The present invention provides a combination of (i) an immune checkpoint modulator and (ii) a T-cell redirecting multifunctional antibody, or an antigen binding fragment thereof, for use in therapeutic treatment of a cancer disease. The T-cell redirecting multifunctional antibody comprises (a) a specificity against a T cell surface antigen; (b) a specificity against a cancer- and / or tumor-associated antigen; and (c) a binding site for human FcγRI, FcγRIIa and / or FcγRIII, wherein the antibody, or the antigen binding fragment thereof, binds with a higher affinity to human FcγRI, FcγRIIa and / or FcγRIII than to human FcγRIIb.

The invention provides a specific T cell receptor targeting KRAS G12V mutant epitope peptide (such as an amino acid sequence as shown in SEQ ID NO: 2) and anti-tumor application of the specific T cell receptor. The specific T cell receptor is composed of two peptide chains alpha and beta and can be specifically combined with a VVGAVGVGK-HLA-A * 11: 01 compound. The invention also provides an antigen binding fragment of the specific T cell receptor, a nucleic acid sequence for coding the T cell receptor, a vector containing the nucleic acid sequence, an engineered cell for expressing the T cell receptor, a composition containing the T cell receptor and application thereof. In addition, the invention also provides a method for screening the KRAS G12V specific T cell receptor. The specific T cell receptor and the antigen binding fragment thereof provided by the invention can be used as an immune effect activator to stimulate the immune response of a body, so that the effect of resisting diseases such as tumors and the like is achieved.

The invention provides a group of specific antibodies for detecting botulinum toxin A and application thereof, and belongs to the technical field of botulinum toxin detection. The invention provides a group of specific antibodies for detecting botulinum toxin A or antigen binding fragments thereof. The specific antibodies or the antigen binding fragments thereof comprise a rabbit monoclonal antibody 1F11 or an antigen binding fragment thereof and a rabbit monoclonal antibody 2A10 or an antigen binding fragment thereof. The time-resolved immunodetection kit prepared by the invention has good detection sensitivity, specificity, repeatability and sample matrix tolerance, the detection range is 0.02 ng / mL-10 ng / mL, the detection limit is 0.02 ng / mL, cross reaction with other serotype botulinum toxins (B, E and F) does not exist, and the time-resolved immunodetection kit is not influenced by sample matrixes such as ham sausages and thick broad-bean sauce. The detection system established by the invention has a good application prospect in detection of botulinum toxin type A.

The present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to human cMET. The disclosure also provides polynucleotides encoding the antibodies or antigen binding fragments thereof, vectors comprising the polynucleotides, host cells comprising the vectors, methods of generating the antibodies, and compositions comprising the antibodies.

The invention relates to the technical field of antibodies, and provides an anti-CD45 antibody for detecting a white blood cell common antigen based on flow cytometry and application of the anti-CD45 antibody, the antibody comprises at least one of the following CDRs: a heavy chain variable region CDR: an amino acid sequence of SEQ ID NO: 1-3 or a conservatively modified form thereof; and a light chain variable region CDR: SEQ ID NO: 4-6 or an amino acid sequence in a conservative modification form thereof. The antibody or the antigen binding fragment thereof can efficiently and specifically recognize CD45, and can effectively detect the CD45.

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.

The present disclosure provides compositions comprising antigen binding polypeptides. More particularly, the disclosure relates to polypeptides comprising antibodies or antigen binding fragments thereof, nucleic acids encoding the polypeptides, and vectors for expressing the same.

The invention relates to a monoclonal antibody aiming at respiratory syncytial virus F protein, a detection reagent based on the monoclonal antibody and application of the monoclonal antibody. According to the present invention, the monoclonal antibody or the antigen binding fragment thereof can specifically bind with the respiratory syncytial virus F protein with high affinity in vivo or in vitro, and has broad-spectrum effectiveness on various genotypes, such that the huge potential application value is provided in the clinical detection of respiratory syncytial virus infection.

The invention belongs to the technical field of biology, and particularly relates to a mouse hepatitis virus antibody or an antigen binding fragment thereof as well as a preparation method and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind to the mouse hepatitis virus or the NSP3 protein thereof, and has good affinity with the mouse hepatitis virus or the NSP3 protein thereof; the kit can be used for preparing products for diagnosing, preventing and / or treating mouse hepatitis virus infection or diseases caused by the mouse hepatitis virus infection, detecting existence or level of mouse hepatitis virus or NSP3 protein in a sample, screening medicines for preventing and / or treating the mouse hepatitis virus infection or the diseases caused by the mouse hepatitis virus infection, and carrying out basic research and / or vaccine development.

Relates to a multispecific antibody or antigen binding fragment specifically binding to LIGHT and GM-CSFR alpha, a composition containing the antibody or antigen binding fragment specifically binding to LIGHT and the antibody or antigen binding fragment specifically binding to GM-CSFR alpha, a pharmaceutical composition containing the multispecific antibody or composition, and a preparation method and application thereof. Including methods of using the same to prevent and treat inflammatory, respiratory or autoimmune diseases.

The invention belongs to the technical field of immunodetection, and discloses an anti-T3 antibody mAb32 or an antigen binding fragment, the anti-T3 antibody mAb32 or the antigen binding fragment comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1, LCDR2 and LCDR3, the amino acid sequence of the LCDR1 is shown as SEQ ID NO.1, the amino acid sequence of the LCDR2 is IAS, and the amino acid sequence of the LCDR3 is shown as SEQ ID NO.3; the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 are respectively shown as SEQ ID NO. 4-6. When the anti-T3 antibody mAb32 is used for detecting a T3 standard antigen, the detection sensitivity is lower than 0.2 ng / ml, and when a clinical sample is detected through a magnetochemiluminescence method, the correlation with R clinical comparison is good within the sample range of 1-80 pmol / L.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.

The present disclosure provides an anti-LILRB2 antibody or an antigen binding fragment thereof, a pharmaceutical composition comprising the anti-LILRB2 antibody or an antigen binding fragment thereof, and uses thereof.

Myocilin-binding agents including antibodies and antigen binding fragments thereof and fusion proteins that immunospecifically bind the coiled-coil domain of myocilin but do not bind to misfolded myocilin are provided herein. The disclosed antibodies and antigen binding fragments and fusion proteins are useful for the detection and extraction of natively folded myocilin from a sample.

In alternative embodiments, provided are chimeric, synthetic or recombinant antibodies (Ab) against the human homologous box NKX-2. 1 (also known as NK2 homologous box 1, or thyroid transcription factor 1 (TTF-1)) protein, including articles of manufacture and kits comprising them, and methods of making and using them, including, for example, their use in the detection or diagnosis and treatment of cancer. In alternative embodiments, an anti-NKX-2. 1 (TTF-1) antibody provided herein is used with an agent for determining whether NKX-2. 1 (TTF-1) expression or activity is present, reduced or deleted; or the sensitivity of the specific binding of the Ab or the antigen (Ag) binding fragment or protein (ABP) or the monomer or dimer ABP provided by the invention with the squamous cell carcinoma cells is lower than the sensitivity of the specific binding with the adenocarcinoma cells (or binding with lower affinity), so that false positives of the squamous cell carcinoma are less, and the positive recognition of the lung adenocarcinoma is better.

The invention discloses an anti-dsDNA antibody or an antigen binding fragment thereof, a detection reagent and a kit, and relates to the technical field of biological detection. The anti-dsDNA antibody or the antigen binding fragment thereof provided by the invention comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO. 1; the amino acid sequence of the light chain variable region is as shown in SEQ ID NO. 2. The detection reagent provided by the invention comprises the anti-dsDNA antibody or the antigen binding fragment thereof. The anti-dsDNA antibody or the antigen binding fragment thereof provided by the invention solves the problems of traceability of positive blood and large-scale supply. By applying the scheme of the invention, the anti-dsDNA with high titer, high accuracy and good stability or the antigen binding fragment thereof can be prepared, and a raw material source with excellent performance is provided for the preparation of a calibration product / a positive control product / a quality control product of an anti-dsDNA detection kit.

The present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to human cMET. The disclosure also provides polynucleotides encoding the antibodies or antigen binding fragments thereof, vectors comprising the polynucleotides, host cells comprising the vectors, methods of generating the antibodies, and compositions comprising the antibodies.

The invention discloses an antibody or an antigen binding fragment thereof and a related product and application thereof, and relates to the field of immunodetection, the antibody comprises HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of which the amino acid sequence is shown as SEQ ID NO: 28 and LCDR1, LCDR2 and LCDR3 in a light chain variable region of which the amino acid sequence is shown as SEQ ID NO: 29, the antibody can be specifically combined with HPV18 type E6-E7 fusion protein, and the antibody can be used for detecting the HPV18 type E6-E7 fusion protein. The method has the advantages of high detection sensitivity, good specificity, high accuracy, good repeatability and the like, and provides a way for effective detection of the HPV18 type E6-E7 fusion protein.

The invention relates to an anti-CK18 monoclonal antibody or an antigen binding fragment thereof, a detection reagent based on the anti-CK18 monoclonal antibody, and a preparation method and application of the anti-CK18 monoclonal antibody or the antigen binding fragment. According to the present invention, the anti-CK18 monoclonal antibody or the antigen binding fragment thereof can specifically bind with the CK18 protein or the fragment thereof with the high affinity, such that the low detection lower limit and the high detection sensitivity can be provided when the anti-CK18 monoclonal antibody or the antigen binding fragment thereof is used for the immunological detection of CK18; therefore, the monoclonal antibody or the antigen binding fragment of the monoclonal antibody has extremely high potential to be developed into an immunodetection antibody or a kit of the CK18 protein, or a diagnostic antibody or a diagnostic kit of diseases (such as NASH) related to abnormality of the CK18 protein (such as abnormal expression level), and has relatively great clinical application prospect and value.

The present invention provides an anti-human CD47 antibody or an antigen-binding fragment thereof, a preparation method and use. The present invention also provides an isolated polynucleotide encoding the antibody or antigen-binding fragment thereof and a vector comprising the isolated polynucleotide of the present invention. The present invention also provides the use of the antibody or antigen-binding fragment of the present invention in the preparation of a medicament for treating and / or preventing a disease that benefits from enhancing an immune response, wherein the disease is cancer.

The invention belongs to the technical field of immunodetection, and discloses an anti-T3 antibody mAb68 or an antigen binding fragment, the anti-T3 antibody mAb68 or the antigen binding fragment comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1, LCDR2 and LCDR3, the amino acid sequence of the LCDR1 is shown as SEQ ID NO.1, the amino acid sequence of the LCDR2 is TAS, and the amino acid sequence of the LCDR3 is shown as SEQ ID NO.3; the heavy variable region comprises HCDR1, HCDR2 and HCDR3, and the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 are respectively shown as SEQ ID NO. 4-6. When the anti-T3 antibody mAb68 is used for detecting a T3 standard antigen, the detection sensitivity is lower than 0.2 ng / ml, a clinical sample is detected through a magnetochemiluminescence method, and the correlation with R clinical comparison is good within the sample range of 1-80 pmol / L.

The present application relates to an antibody capable of specifically binding to c-Met or antigen-binding fragment thereof, and an immunoconjugate, a pharmaceutical composition and a multispecific molecule comprising the same. The present application further relates to the use of the antibody specifically binding to c-Met or an antigen-binding fragment thereof and the multispecific molecule. Compared with the control antibody, the bispecific antibody or defucosylated bispecific antibody of the present application can block HGF-dependent TKI resistance; block the proliferation and migration of tumor cells induced by HGF, induce ADCC effect, and inhibit tumor growth in vivo.

The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.

The invention discloses a reagent and a method for detecting berberine-resistant viruses. The reagent provided by the invention comprises an antibody or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR1-3 and / or a light chain complementarity determining region LCDR1-3, the heavy chain complementarity determining region HCDR1-3 has a sequence as shown in SEQ ID NO.5-7, and the light chain complementarity determining region LCDR1-3 has a sequence as shown in SEQ ID NO.8-10. The reagent can be used for detecting the berberine-resistant herpes simplex virus type 1, so that the treatment effect can be evaluated in advance before berberine is applied for treatment.

The present invention provides an anti-CCR9 antibody or antigen binding fragment thereof comprising a variable light chain comprising SEQ ID NO:1 or a variant thereof having at least 95% sequence identity to SEQ ID NO:1, wherein the variable light chain comprises a CDR-L1 comprising the amino acid sequence RSSQSLXHSNGXTFLH (SEQ ID NO: 2), a CDR-L2 comprising the amino acid sequence KVSNRFS (SEQ ID NO: 3) and a CDR-L3 comprising the amino acid sequence SQTTHXPWT (SEQ ID NO: 4), wherein X can be any amino acid. Also provided is the anti-CCR9 antibody or antigen binding fragment thereof for use in the treatment or prevention of a disease, as well as methods of diagnosis and antibody drug conjugates.